Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Publikationen
Suchbegriffe: BEVACIZUMAB - THERAPEUTIC USE , . Treffer: 4
2023
Pujade-Lauraine, E; Brown, J; Barnicle, A; Wessen, J; Lao-Sirieix, P; Criscione, SW; du, Bois, A; Lorusso, D; Romero, I; Petru, E; Yoshida, H; Vergote, I; Colombo, N; Hietanen, S; Provansal, M; Schmalfeldt, B; Pignata, S; Martín, Lorente, C; Berton, D; Runnebaum, IB; Ray-Coquard, I
Homologous Recombination Repair Gene Mutations to Predict Olaparib Plus Bevacizumab Efficacy in the First-Line Ovarian Cancer PAOLA-1/ENGOT-ov25 Trial.
JCO Precis Oncol. 2023; 7:e2200258
Doi: 10.1200/PO.22.00258
[OPEN ACCESS]
PubMed
FullText
FullText_MUG
2020
Zhou, Q; Perakis, SO; Ulz, P; Mohan, S; Riedl, JM; Talakic, E; Lax, S; Tötsch, M; Hoefler, G; Bauernhofer, T; Pichler, M; Gerger, A; Geigl, JB; Heitzer, E; Speicher, MR
Cell-free DNA analysis reveals POLR1D-mediated resistance to bevacizumab in colorectal cancer.
Genome Med. 2020; 12(1):20
Doi: 10.1186/s13073-020-0719-6
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
2017
Eisterer, W; Piringer, G; DE Vries, A; Öfner, D; Greil, R; Tschmelitsch, J; Samonigg, H; Sölkner, L; Gnant, M; Thaler, J; Austrian Breast and Colorectal Cancer Study Group
Neoadjuvant Chemotherapy with Capecitabine, Oxaliplatin and Bevacizumab Followed by Concomitant Chemoradiation and Surgical Resection in Locally Advanced Rectal Cancer with High Risk of Recurrence - A Phase II Study.
Anticancer Res. 2017; 37(5):2683-2691
Doi: 10.21873/anticanres.11617
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
2016
Svejda, B; Muschitz, Ch; Gruber, R; Brandtner, Ch; Svejda, Ch; Gasser, RW; Santler, G; Dimai, HP
[Position paper on medication-related osteonecrosis of the jaw (MRONJ)].
Wien Med Wochenschr. 2016; 166(1-2):68-74
Doi: 10.1007/s10354-016-0437-2
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG